

## **Diacomit (Stiripentol)**

### **POLICY**

#### **I. CRITERIA FOR APPROVAL**

An authorization of 12 weeks may be granted when all the following criteria are met:

- A. Patient has a documented diagnosis of Dravet Syndrome and the diagnosis has been confirmed by two unaffiliated neurologists/epileptologists
- B. Medication is being prescribed by a neurologist or epileptologist
- C. Patient is 6 months of age and older and documentation that patient weighs 7kg or more
- D. Patient is currently taking clobazam
- E. Documentation of baseline neutrophil and platelet count obtained prior to starting treatment

#### **II. CONTINUATION OF THERAPY**

Authorization of 12 months may be granted for all members who are tolerating treatment and has had a documented 50% reduction in frequency per 30 days of generalized clonic or tonic-clonic seizures.

#### **III. QUANTITY LIMIT**

Diacomit 250mg: 180 caps/packets per 30 days  
Diacomit 500mg: 180 caps/packets per 30 days

#### **IV. REFERENCES**

1. Diacomit [package insert]. San Mateo, CA: Biocodex, Inc.; July 2022.